CD1D and neoplasm: Additionally, CD1d+ CD19+ lymphoma cells have been targeted by CAR-iNKT cells in a dual pronged attack which effectively localised to the tumour site, had potent anti-tumour activity, and significantly improved the long-term survival of treated mice (89).